Evidence map›Paper›PMID 36405039›Full record

ArticleEuropean physical journal plus2022

Targeting highly resisted anticancer drugs through topological descriptors using VIKOR multi-criteria decision analysis.

Yali Li, Adnan Aslam, Saadia Saeed, Guoping Zhang, Salma Kanwal

Abstract read
In one paragraph

Article in European physical journal plus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Predictive modelling and ranking:Frontiers in chemistry · 2025
    Article
  5. Article
  6. Prioritizing Asthma Treatment Drugs through Multicriteria Decision Making.International journal of analytical chemistry · 2024
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yali LiSchool of Software, Pingdingshan University, Pingdingshan, 467000 China.
Adnan AslamDepartment of Natural Sciences and Humanities, University of Engineering and Technology, Lahore (RCET), Pakistan.
Saadia SaeedDepartment of Mathematics, Lahore College for Women University, Lahore, Pakistan.
Guoping ZhangSchool of Software, Pingdingshan University, Pingdingshan, 467000 China.
Salma KanwalDepartment of Mathematics, Lahore College for Women University, Lahore, Pakistan.ORCID 0000-0002-8329-4686

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The disease cancer is expanding on high spans in virtually all over the world, and undoubtedly, the research through all the aspects of sciences for each of its perspective is a great cause in reducing its severeness and symptoms. Chemotherapy is itself a cure to cancer as it helps in controlling the formation of cancerous cells but leaving multiple side effects on a human body. In this research work, we targeted 21 anticancer drugs that are in taken by the patients in combinations during chemotherapies. We introduce another branch of mathematics named as OR (Operations Research) linking to the chemical graph theory. Chemical graph theory allows us to generate highly resistant research on any structure via quantitative structure property relationship (QSPR) modeling to explore and develop new compounds for drugs. In this research study, we visualized what else the QSPR could provide when it comes to ranking drugs. We visualized the results obtained for boiling points and enthalpy of vaporizations through QSPR as the values of correlation coefficients and the errors generated under unique QSPR modeling. The implementation of VIKOR provides the best ranking for each of anticancer drugs when keeping in concern the specified properties, and the conclusions from this research work show another path to biologist scientists to create best combinations keeping in concern the study generated from QSPR. Supplementary Information: The online version contains supplementary material available at 10.1140/epjp/s13360-022-03469-x.

Identifiers

PMID36405039
PMCPMC9667010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.